Radiopharmaceutical Production Faces New Capacity Hurdles
Experts at EANM 2026 highlight a reliance on aging reactors as research shifts toward new targets like ACP3.
Updated on Oct. 21, 2026 in Nuclear
Live Poll
Should medical systems prioritize expanding existing treatment availability over developing experimental new cancer therapies?
At the October 2026 EANM conference in Vienna, experts analyzed the state of radiopharmaceutical production and future development trends. The discussion highlighted a critical European reliance on aging research reactors and the ongoing effort to expand targeted therapy options.
Why it matters
Radiopharmaceutical development is currently constrained by production capacity and rising costs, necessitating innovation to bring new diagnostic and therapeutic agents to patients. Advancements in targets like ACP3 aim to broaden treatments beyond prostate cancer to include breast, ovarian, and lung malignancies.
Current development utilizes emerging targets such as ACP3 for PSMA-targeted therapy, aiming to improve upon existing radioligand protocols. Production efficiency remains the primary bottleneck for scaling these therapies as the industry shifts toward personalized treatment.
The players
Wolfgang Wadsak
Chair of the EANM Guidelines and Publications Council who oversees clinical radiopharmaceutical preparation at the MINUTE medical clinic in Vienna.
EANM
The European Association of Nuclear Medicine, an organization that sets standards and publishes guidelines for the field of radiopharmaceutical medicine.
The details
Radiopharmaceuticals are compounds that combine a radioactive isotope with a targeting molecule to deliver localized radiation directly to diseased tissue. PSMA-targeted therapy works by attaching these isotopes to molecules that bind to Prostate-Specific Membrane Antigen, a protein often overexpressed on the surface of cancer cells. The integration of new targets like ACP3 — a potential marker for other tumor types — seeks to expand the range of diseases treatable with this mechanism. Future development focuses on administering these therapies earlier in the patient care sequence to improve outcomes.
Timeline
October 2026: The EANM 2026 conference took place in Vienna.
The Tech Race
This development follows the trajectory set at the EANM 2026 conference to standardize clinical pathways for radiopharmaceuticals. It highlights a critical industrial race to move beyond dependence on aging research reactors while expanding targeting molecules like ACP3.
Patients with advanced prostate cancer may eventually see earlier access to PSMA-targeted therapies as clinical guidelines evolve. However, broad availability remains contingent on overcoming current production capacity constraints within the European nuclear infrastructure.
The takeaway
The field is moving toward earlier intervention and more diverse oncological targets beyond traditional prostate cancer treatments. Stakeholders should monitor upcoming European investment plans regarding research reactor infrastructure as a lead indicator for clinical availability.
Further reading
Explore the latest developments in nuclear medicine on our Nuclear page.
Source note: This article includes information reported by AuntMinnieEurope.
Live Poll
Should medical systems prioritize expanding existing treatment availability over developing experimental new cancer therapies?
